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Abstract
Introduction Femoral and patellar cartilage defects with a defect size > 2.5 cm2 are a potential indication for an autologous
chondrocyte implantation (ACI). However, the influence of the localization and the absolute and relative defect size on the
clinical outcome has not yet been determined. The purpose of this study is to analyze the influence of the localization and the
absolute and relative defect size on the clinical outcome after third-generation autologous chondrocyte implantation.
Methods A total of 50 patients with cartilage defects of the knee were treated with third-generation autologous chondrocyte
implantation (Novocart® 3D). A match paired analysis was performed of 25 treated femoral and 25 treated patella defects with a
follow-up of three years. MRI data was used to do the manual segmentation of the cartilage layer throughout the knee joint. The
defect size was determined by taking the defect size measured in the MRI in relation to the whole cartilage area. The clinical
outcome was measured by the IKDC score and VAS pre-operatively and after six, 12, 24, and 36 months post-operatively.
Results IKDC andVAS scores showed a significant improvement from the baseline in both groups. Femoral cartilage defects showed
significantly superior clinical results in the analyzed scores compared to patellar defects. The femoral group improved IKDC from 33.9
(SD 18.1) pre-operatively to 71.5 (SD 17.4) after three years and the VAS from 6.9 (SD 2.9) pre-operatively to 2.4 (SD 2.5) after
three years. In the patellar group, IKDC improved from 36.1 (SD 12.6) pre-operatively to 54.7 (SD 20.3) after three years and the VAS
improved from 6.7 (SD 2.8) pre-operatively to 3.4 (SD 2.) after three years. Regarding the defect size, results showed that the same
absolute defect size at med FC (4.8, range 2–15) and patella (4.6, range 2–12) has a significantly different share of the total cartilaginous
size of the joint compartment (med FC: 6.7, range 1.2–13.9; pat: 18.9, range 4.0–47.0). However, there was no significant influence of
the relative defect size on the clinical outcome in either patellar or femoral localization.
Conclusion Third-generation autologous chondrocyte implantation in ACI-treated femoral cartilage defects leads to a superior
clinical outcome in a follow-up of three years compared with patellar defects. No significant influence of the defect size was
found in either femoral or patellar cartilage defects.
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Introduction
Full-thickness cartilage defects are pre-arthritic lesions and
can produce significant pain and disability for patients [1, 2].
The intrinsic regeneration capability of the cartilage is very
limited and the healing likelihood of once damaged cartilage
is reduced. Many studies have proven that autologous chon-
drocyte implantation (ACI) represents an appropriate method
for treatment of larger full-thickness cartilage defects in knees
and leads to significant improvement [3–9].
Since the first-generation ACI, using a periosteal flap, there
have been many improvements in this procedure including
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using a collagenous membrane (second-generation ACI) or a
3D collagenous scaffold (third generation) [10]. The available
studies researching the possible influencing factors (site, le-
sion size, etiology, age, location etc.) on the outcome of ACI
have shown various results [11–18]. As for the localization,
the defects on femoral condyle reached excellent mid-term
and long-term clinical outcomes, while patellar-located le-
sions were associated with less successful clinical outcomes
[11–13, 19]. The improvement of the ACI technique and the
concomitant correction of the patellofemoral malalignment
improved the outcome of the patellar defects [15, 17].
Despite these improvements, using the ACI on the patella
remains controversial and with unclear results, which are
worth researching.
There are only a few studies analyzing the third generation
of the ACI focusing on the localization of the defect and com-
paring the femoral with patellar defects [20, 21]. According to
current recommendations, the defect size of 2.5–3 cm2 and
larger is regarded as a potential indication for the ACI [7,
22]. However, it is not known whether this “critical” limit is
identical for the different knee compartments as patella and
condyles or whether a differentiated size consideration with
relative defect size (damaged area in relation to the total com-
partment) for these compartments is needed. The correlation
between the outcome and the absolute defect size measured
intra-operatively was the focus of previous studies showing
various results [23, 24]. The relative defect size had not been
researched and evaluated until this study.
The aim of our research is to analyze the influence of the
localization and the defect size on the clinical outcome follow-
ing third-generation ACI. Our hypothesis was that patellar
defects and defects with a bigger share on the whole cartilage
layer of the knee compartment lead to less successful
outcomes.
Methods
Our data were captured between 2004 and 2018 with a local
Institutional Review Board approval. All patients from our
database with femoral and patellar cartilage defects of the
knee classified as International Cartilage Repair Society
(ICRS) grades III and IV were included in our prospective
study and treated with third-generation ACI with intact me-
niscus and corresponding joint surfaces. We intended to per-
form a matched pair analysis. The criteria for the pair
matching were age, sex, body mass index, numbers of treated
defects, and the intra-operatively measured absolute defect
size (Table 1). The first group represented 25 patients with
medial condyle defects, while the second group consisted of
25 matched patients with patellar defects. All patients were
treated with Novocart® 3D (TETEC AG, Reutlingen,
Germany), a third-generation ACI.
For precise detection of the absolute defect size, magnetic
resonance imaging (MRI) examinations were performed
(Magnetom-Sonata; Siemens, Germany) with a conventional
circular polarizing 1-channel knee coil three months post-op-
eratively. The following sequences were performed: the fast
spin-echo (dual T2-FSE), the fat-saturated gradient echo (3D
FS GE), the proton-weighted fat-saturated T1-weighted se-
quence, and a fast-low-angle shot sequence (FLASH) with
selective water excitation, all sequences suitable for the mea-
surement of articular cartilage in the knee joint. DICOM
(Digital Imaging and Communications in Medicine) data sets
were used in the open source software 3D Slicer to do a man-
ual segmentation of the cartilage layer and of the defect. 3D
Slicer is a free software platform for the analysis and visuali-
zation of medical images. After the segmentation of the carti-
lage layer and the cartilage defect, we determined the relative
defect size by putting the defect size into relation with the
cartilage volume size of the medial femoral condyle/patella,
which represented the relative defect size in % (Fig. 1) using
the ParaView (Kitware, Clifton Park, New York, USA) and
custom-made software [25].
Patient-reported outcomes were measured pre-operatively
and at six, 12, 24, and 36 months post-operatively using the
clinical scores IKDC (International Knee Documentation
Committee) subjective knee form and a visual analog scale
(VAS). Additionally, patient-specific parameters such as
age, gender, and body mass index (BMI), as well as defect-
specific data such as defect size or localization, were collected.
For the statistical analysis of the clinical data, the statistic
program SPSS (Statistical Package for the Social Sciences,
Chicago, IL, USA) was used. For the detection of significant
differences between the two groups at the same time of inves-
tigation, the Wilcoxon or Friedman test was carried out for
paired samples. To compare multiple groups of non-related
samples at one point, the Mann–Whitney U test was used.
Pearson’s correlation models were used to distinguish associ-
ations between influencing factors and clinical knee scores.
Our primary outcome parameter was the IKDC score, second-
ary outcome the VAS. A post hoc power analysis was per-
formed with an effect size of 0.916. A statistically significant
result of p < 0.05 was reported.
Results
There were a total of 50 patients in two matched groups with
25 patients in each study group. As previously explained, all
the known influencing factors were removed by matching.
The average age of the femoral group was 34.6 years (15–
53), 11 male and 14 females, with the mean body mass index
(BMI) of 27.3 kg/m2 (20–36). Themean intra-operative defect
size was 4.8 cm2 (2–15). In the matched pair group with ACI
patients, in the patellar group, the average age was 33.3 years
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(13–56), ten male and 15 females with a mean BMI of
26.3 kg/m2 (19–35) and average intra-operative defect size
of 4.6 cm2 (2–12). Patient characteristics are described in
Table 1. In 6 (24%) cases in the femoral group, concomitant
surgery was carried out (4 cancellous bone grafting and 2
anterior cruciate ligament reconstructions). In the patellar
group, nine (36%) concomitant surgery (8 stabilization of
the medial retinaculum and 1 high tibial osteotomy) were
performed. Previous surgery was performed in nine cases in
the patellar group (bone marrow stimulation n = 7, cartilage
shaving n = 1, high tibial osteotomy n = 1) and nine cases in
the femoral group (bone marrow stimulation n = 8, refixation
flake fracture n = 1).
Localizations
In both groups, a significant IKDC improvement within the
group in comparison to pre-operative values (pre-operative vs.
6, 12, 24, 36 months; p < 0.05) (Fig. 2) was found at all
timepoints. In the femoral group, the IKDC subjective score
was 33.9 (3–67) pre-operatively and 56.4 (28–93) after
six months. Afterwards, we observed further increasing
IKDC score to 66.7 (25–95) after 12 months and 70.2 (48–
100) after two years. The maximum value 71.5 (40–100) was
reached after three years (Table 2). The patellar group showed
an IKDC subjective score of 36.1 (14–65) pre-operatively. Six
months pos-toperatively, it was 47.5 (22–78) and the 12-
month value was 54.3 (23–81). After two years, the maximum
IKDC value was reached with 57.7 (16–93). A slight decrease
was seen after three years to 54.7 (22–92).
Comparing the IKDC results of our two groups over a period
of three years, we found a significant difference between the two
groups. The IKDC score showed a significant difference between
the two groups one to three years post-operatively (p < 0.05). At
all post-operative timepoints, the IKDC value of the femoral
group was better than of the patellar group. Only after
six months was the difference (p > 0.05) statistically not signifi-
cant. In the following timepoints, significant differences of IKDC
score were noticed (after 1 year p= 0.016, 2 years p= 0.030, and
3 years p = 0.009) (Fig. 1; Table 2).
The results of the visual analog scale (VAS) also showed a
statistically significant improvement over time. In the femoral
group, the patients assessed the VAS at rest pre-operatively with
an average of 2.6 (0–8). Post-operatively, the VAS at rest was
0.57 (0–6), 0.87 (0–5), 0.53 (0–4), and 0.78 (0–5) measured 6,
12, 24, and 36 months after ACI, which means a significant
improvement at all timepoints (Table 2; Fig. 2). In the patellar
group, a significant improvement (p< 0.05) of the VAS at rest
scalewas seen at post-operativemeasurements after 12 (p < 0.01)
and 24 months (p < 0.002). As for the VAS at movement, there
was a significant improvement measured at all times post-
operatively in both femoral and patellar groups (p< 0.02). The
rate of the VAS at movement in the femoral group pre-
operatively was 6.9 (0–10) and improved to 1.8 (0–8) at
24 months and to 2.4 (0–9) at 36 months post-operatively.
Similarly, in the patellar group, VAS at movement improved
from 6.7(0–10) pre-operatively to 3.4 (0–9) after 36 months
(Table 2; Fig. 3). Comparing the two groups, a statistically sig-
nificant difference between the two groups was shown two years
post-operatively for VAS at movement (p = 0.004) and
six months post-op for VAS at rest (p= 0.005) (Table 2).
Defect size
The mean relative defect share on the knee was 12.8% (1.2–
47.7). In the femoral group, the average relative defect was
6.7% (1.2–13.9), while in the patellar group, it was 18.9%
(4.0–47.7) (Fig. 4). Comparing these relative defects sizes, we
found a significant difference between the medial femoral con-
dyle and the patella group. This means that the same absolute
defect size at medial femoral condyle and patella has a signifi-
cantly different (p< 0.05) share on the total cartilage size of the
joint compartment (relative defect size). It is graphically summa-
rized in Fig. 4. In analyzing the influence of the relative defect
size on the clinical outcome measured by IKDC and VAS, no
statistically significant correlation was found (p> 0.05). As for
the absolute defect size, no statistically significant correlation
between the outcome and the absolute defect size was found.
Discussion
The major findings of this study are that the third-generation
ACI in femoral treated cartilage defects leads to a superior
Table 1 Patient characteristics
Med FC Patella
Number of patients 25 25
Gender, n (%) Male 11 (44) 10 (40)
Female 14 (56) 15 (60)
Intraoperative defect size in cm2 (range; SD) 4.83 (2–15; 2.79) 4.61 (2–12; 2.39)
BMI in kg/m2 (range; SD) 27.3 (20–36; 4.68) 26.3 (19–35; 4.83)
Age in years (range; SD) 34.6 (15–53; 12.38) 33.2 (13–56; 12.51)
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clinical outcome in a follow-up of three years compared with
ACI-treated patellar cartilage defects and that the relative and
absolute defect sizes do not have a significant influence on the
outcome.
The third-generation ACI is an established and accepted
method for the treatment of full-thickness cartilage defects in
the knee as has been proven in many studies [6, 26]. The evi-
dence on the success of the ACI has increased significantly dur-
ing the past years [27–29]. The efficacy of this procedure has
been demonstrated in multiple studies showing a positive effect,
with increased function and pain reduction [3–5, 16, 19, 30]. The
ACI with its cell expansion in vitro and the whole process is an
expensive method of the cartilage therapy [31]. Therefore, the
indication for using this procedure should be as clear as possible.
All influencing factors are still the focus of many studies.
Since the introduction of ACI, several studies have described
factors that influence its clinical outcome. There are patient-
related (sex, age, BMI, physical activity) and defect-related (le-
sion size, location, prior procedures, etiology) aspects that can
influence the results of the ACI [32]. The studies investigating
the significant correlation of these factors with the outcomes
have showed heterogeneous results. Some previous research de-
scribed that female sex and chronic aetiology are associated with
inferior outcomes [18, 33]. Regarding age and BMI as factors,
some studies have shown the disadvantageous effects of higher
patient age and BMI on the outcome of ACI [33–35].
Filardo et al. in a large matrix-associated ACI cohort present-
ed the disadvantage of higher agewith the degenerative aetiology
and the benefit of male sex with higher physical activity. On the
other hand, Vasiliadis et al. and Kon et al. described no associ-
ation between clinical outcomes and age, and Gobbi et al.
showed no correlation with aetiology [27, 33, 36]. Regarding
prior procedures, a study regarding the negative influence of prior
cartilage procedures has been published [37, 38].
In terms of influencing factors, in our study, we focused on
the localization and the defect size. We removed other influenc-
ing factors by matching. The patellar-located lesions have been
associated with lower clinical outcomes [19, 35], despite the
correction of the patellar malalignment showed clinical improve-
ment [17, 39, 40]. In our study, we only analyzed the third-
generation ACI. There are few studies focusing on localization
analyzing only the third-generation ACI to compare our results
with. Gigante et al. did not see a significant difference between
various localizations of the defect in his small sample of patients
[41]. Filardo et al. compared third-generation ACI in patellar vs.
trochlear region, with significant superiority for trochlear lesions.
In another study from this group, condyle and trochlear lesions
Table 2 Clinical outcomes of medial femoral condyle (med FC) and patella group over the time
Pre-operative 6 months 12 months 24 months 36 months
Med FC IKDC (range; SD) 33.9 (3–67; 18.13) 56.4 (28–93; 17.14) 66.7 (25–95; 19.35) 70.2 (48–100; 14.66) 71.5 (40–100; 17.47)
VAS at movement
(range; SD)
6.90 (0–10; 2.90) 3.60 (0–9; 3.10) 2.81 (0–9; 2.74) 1.83 (0–8; 2.23) 2.40 (0–9; 2.50)
VAS at rest (range; SD) 2.63 (0–8; 2.69) 0.57 (0–6; 1.36) 0.87 (0–5; 1.44) 0.53 (0–4; 1.04) 0.78 (0–5; 1.48)
Patella IKDC (range; SD) 36.1 (14–65; 12.59) 47.4 (22–78; 17.46) 54.3 (23–81; 15.48) 57.7 (16–93; 18.59) 54.7 (22–92; 20.31)
VAS at movement
(range; SD)
6.71 (0–10; 2.81) 4.71 (1–10; 2.63) 4.14 (1–9; 2.45) 4.51 (1–10; 3.15) 3.40 (0–9; 2.49)
VAS at rest (range; SD) 2.66 (0–9; 3.06) 1.8 (0–5.5; 1.92) 0.57 (0–3.7; 0.95) 0.7 (0–3.4; 0.99) 1 (0–3; 1.1)


















Fig. 2 The evolution of the IKDC results of the two groups over a period
of three years. In both groups, there was a significant improvement in
comparison to pre-operative values at all timepoints. At 12, 24, and
36 months was the IKDC value of the med FC group significantly better
(marked with *) than the patellar group (6 months p = 0.101, 1 year p =
0.0.016, 2 years p = 0.030, and after 3 years p = 0.009)
Fig. 1 The DICOM (Digital Imaging and Communications in Medicine)
datasets were used in the open source software 3D Slicer to do the manual
segmentation of the cartilage layer and of the defect (a). In the further
post-processing using the ParaView and YBones software, the share of
the defect on the cartilage layer of the knee compartment, which repre-
sented the relative defect size in %, was calculated. The violet part in the
picture is the femoral defect, and the white part represents the cartilage
layer (b)
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were compared with slightly better results for trochlear [42]. In
the study of Gobi et al., ACI patients with trochlear lesions
showed better results than those with patellar lesions [43]. We
did not analyze the trochlear lesion at all. Meyerkort et al. de-
scribed good clinical improvement with KOOS score > 70
five years after patellofemoral ACI but did not analyze the fem-
oral localization [40].
Welsch et al. investigated the MACI comparing patella vs.
med FC lesions and found no significant difference from the
radiological point of view without clinical outcome scores [21].
Kon et al. analyzed the long-term results of the patellar ACI
without comparing other localizations, proving no clinical
worsening over the time in patellar lesion, despite his previous
finding at mid-term results [36]. Ebert et al. showed a significant
difference between femorotibial and patellofemoral KOOS
scores [44]. In a recent study, Niemeyer et al. presented no sig-
nificantly better results for patellar defects than femoral using the
matrix-associated ACI with spheroid technology [20].
With the increasing number of ACI procedures, there are
now many studies focusing attention on the size of the defect.
In all of the available studies, the focus of interest is the abso-
lute defect size measured intra-operatively. According to ac-
tual recommendations, defect size from 2.5 to 3 cm2 and larger



































Fig. 3 The comparison of the
VAS at rest (a) and at movement
(b) in med FC and pat group. The
VAS at rest in med FC reached a
significant improvement 6, 12,
24, and 36 months after ACI. In
the pat group, a significant
improvement (p < 0.05) of the
VAS at rest scale was seen at
post-operative measurements af-
ter 12 (p < 0.01) and 24 months
(p < 0.002). As for the VAS at
movement, there was a significant
improvement measured at all
times post-operatively in both
medial femoral condyle (med FC)
and patella groups (p < 0.02)
(*Stands for significance in both
group)
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thought that treatment of large defects was associated with an
increased risk of failure [24]. However, there are now many
studies that did not find any correlation between outcomes and
the absolute defect size [14, 23, 27]. In our study, we also did
not find any correlation between outcome and absolute defect
size.
To our knowledge, there is no study investigating the rela-
tive defect size as the share of the defect on the whole cartilage
layer of the knee compartment. Therefore, in our study, we
analyzed the absolute and relative defect size, which we ob-
tained by comparing the defect size measured in the MRI in
relation to the whole size of the knee compartment. We
showed that the same absolute defect size at medial femoral
condyle and patella has a significantly different share on the
total size of the joint compartment (relative defect size)
(p < 0.05). Nevertheless, it had not been proven in our further
analysis if the relative defect size had no significant influence
on the clinical outcome (p > 0.05). According to our results,
neither the absolute nor the relative defect size has a signifi-
cant influence on outcomes and could not explain the inferi-
ority of the patellar clinical outcome.
A potential negative effect of the worse clinical outcome in
patellar defects is the complexity of the patellofemoral joint.
Maltracking or patella instability is causing most of the patel-
lar cartilage defects. Concomitant surgery is often needed. In
this study, we could not find negative effects of concomitant
surgery in general in both groups. Also, there was no negative
effect regarding the treatment of patella instability. In 8 patel-
lar patients, additional stabilization of the patella was per-
formed without worse clinical outcomes (p > 0.005).
A limitation of our study is the relatively small number of
patients (n = 50), with 25 in each group and a relatively short
follow-up of three years. A larger study would be helpful to
have stronger reliability in our findings and would enable the
possibility of getting the significant results for relative defect
sizes. Long-term follow-up would also bring us more infor-
mation about the durability and further development of our
results. The next limitation could be the missing matching for
aetiology of the defects. When interpreting the results of the
present study, lack of randomization should be kept in mind,
which reduces the level of evidence from I to III.
Conclusion
Third-generation ACI provides clinical benefits for both pa-
tellar and femoral defects. In a follow-up of three years, ACI-
treated femoral cartilage defects showed superior clinical out-
comes compared with patellar defects. No significant influ-
ence of the relative or absolute defect size was found in either
femoral or patellar cartilage defects.
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